Business
TNI BioTech, Inc. Obtains Drug Approval For Sale of Low Dose Naltrexone (LDN) From Government of Malawi
TNI BioTech, Inc. Obtains Drug Approval For Sale of Low Dose Naltrexone (LDN) From Government of Malawi.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nTNI BioTech, Inc. Obtains Drug Approval For Sale of Low Dose Naltrexone (LDN) From Government of Malawi\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTNI BioTech, Inc. Obtains Drug Approval For Sale of Low Dose Naltrexone (LDN) From Government of Malawi\nPR Newswire\nORLANDO, Fla., May 6, 2014\n\n\n\nORLANDO, Fla., May 6, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTCQB: TNIB) (\"TNI BioTech\"), a biotechnology company focused on the development, marketing and distribution of opioid-related immunotherapies, today announced that effective as of April 16, 2014, it has successfully obtained approval from the Government of Malawi's drug regulatory authority, the Malawi Pharmacy, Medicines and Poisons Board, for the marketing and sale of Low Dose Naltrexone (LDN) in Malawi for the treatment of patients with cancer. \n\n\"The Government of Malawi's approval of LDN, to be distributed under the trade name Lodonal™, represents a monumental and historical achievement for TNI BioTech and was not possible without the support of the medical community in Malawi, which by this step and our collective ongoing work recognizes the importance of the treatment of cancer. TNI BioTech is grateful to the many people whose tireless efforts have made this day possible. This is an important milestone as we seek approval for sale of LDN in additional emerging nations and hope to bring our drug therapies to those in need worldwide,\" said Noreen Griffin, Chief Executive Officer of TNI BioTech. \n\nDr. Ndiouga Dieng, Vice President, African Affairs for TNI BioTech, said, \"The approval of LDN by the Malawi Pharmacy, Medicines and Poisons Board will allow TNI BioTech to deliver on its commitment to sustainable healthcare to Africa. This significant achievement would not be possible without the vision of President Joyce Banda of Malawi and the dedication of Doctor Leo Masamba, Clinical Oncologist of Queen Elizabeth Hospital.\" TNI BioTech expects to begin delivery of Lodonal™ to Malawi within two weeks. The product license enables TNI BioTech to market Lodonal™ in Malawi ...